Author/Editor		Grat, Mateja; Vučković, Joško
Title		Naše izkušnje pri zdravljenju kronične mieloične levkemije z imatinib mesilatom
Translated title		Treatment with imatinib mesylat in chronic myelogenous leukemia - our experience
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 73, št. Suppl 1
Publication year		2004
Volume		str. I-31-3
Language		slo
Abstract		Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity. The normal ABL protein is involved in the regulation of the cell cycle. Fusion oncoprotein deregulates signal transducing pathways, causing an abnormal cell cycling inhibition of apoptosis and increased proliferation of cells. ABL specific tyrosin kinase inhibitors selectively inhibit the growth of BCR-ABL positive cells. Methods. Eleven patients with chronic phase CML were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses and toxic effects. Results. Imatinib induced major cytogenetic response (MCR) in 78% and a complete hematologic response (CHR) in 100% of eleven patients. We observe non hematologic toxic effects in 55% and grade 3 or 4 hematologic toxic effects in 11% of patients. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic phase CML.
Summary		Izhodišča. Kronična mieloična levkemija (KML) je maligna klonska bolezen krvotvornih matičnih celic. Pri večini bolnikov najdemo recipročno translokacijo t(9,22), katere posledica je BCR-ABL onkogen in onkoprotein z aktivnostjo tirozin kinaze. Posledično nastopi deregulacija poti signalne transdukcije z motnjami celičnega cikla, inhibicijo apoptoze in proliferacijo celic ABL specifični zaviralci tirozin kinaze selektivno zavro proliferacijo malignega klona. Metode. Pri 11 bolnikih v kronični fazi KML smo uvedli imatinib 400 mg dnevno. Ocenjevali smo citogenetski in hematološki odgovor ter pojavljanje neželenih učinkov zdravila. Rezultati. Z imatinibom smo dosegli dober citogenetski odgovor pri 78% bolnikov, od tega pri 11% popoln citogenetski odgovor. Pri vseh bolnikih je bila dosežena popolna hematološka remisija 4 tedne po uvedbi zdravila. Neželene učinke smo opazovali pri 55% bolnikov, resnejše hematološke neželene učinke pa pri 11% bolnikov. Zaključki. Pri zdravljenju bolnikov v kronični fazi KML z imatinibom smo dosegli dober citogenetski in popoln hematološki odgovor.
Descriptors		LEUKEMIA, MYELOID, CHRONIC MESYLATES TREATMENT OUTCOME